Pfizer Inc. Declares Quarterly Dividend of $0.43 (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Wednesday, June 24th. Investors of record on Friday, July 24th will be paid a dividend of 0.43 per share by the biopharmaceutical company on Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th.

Pfizer has decreased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 16 consecutive years. Pfizer has a dividend payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $2.86 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 60.1%.

Pfizer Stock Performance

NYSE PFE opened at $24.05 on Thursday. The stock has a market capitalization of $137.07 billion, a price-to-earnings ratio of 18.36 and a beta of 0.34. Pfizer has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average of $26.07 and a 200 day moving average of $26.31.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer will post 2.99 EPS for the current fiscal year.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s FDA approval of an expanded IBRANCE regimen for HR-positive, HER2-positive advanced or metastatic breast cancer adds a new treatment option and supports revenue for an established oncology asset. FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
• Positive Sentiment: Pfizer also declared a quarterly dividend of $0.43 per share, reinforcing the company’s income appeal and signaling continued capital returns to shareholders. Pfizer Declares Third-Quarter 2026 Dividend
• Positive Sentiment: Pfizer Ventures led a $62 million Series B round for Oblenio Bio, a move that suggests Pfizer is still investing in early-stage innovation, especially in autoimmune disease development. Oblenio Bio Closes $62 Million Series B…
• Neutral Sentiment: Pfizer reaffirmed its FY2026 outlook amid a leadership change, which helps reduce near-term uncertainty but does not materially change the growth story. Pfizer Reaffirms FY 2026 Outlook Amid Leadership Change
• Neutral Sentiment: Pfizer was dismissed from a U.S. states’ generic drug price-fixing lawsuit, removing one legal overhang, but the direct financial impact appears limited for now. Pfizer dismissed from US states’ drug price-fixing lawsuit
• Negative Sentiment: The main negative catalyst is the lung cancer trial miss, which is weighing on sentiment because it clouds confidence in Pfizer’s oncology pipeline and the growth expected from acquired assets. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.